EP0980257A1 - Utilisation de particules de type viral en tant qu'adjuvants - Google Patents
Utilisation de particules de type viral en tant qu'adjuvantsInfo
- Publication number
- EP0980257A1 EP0980257A1 EP98919845A EP98919845A EP0980257A1 EP 0980257 A1 EP0980257 A1 EP 0980257A1 EP 98919845 A EP98919845 A EP 98919845A EP 98919845 A EP98919845 A EP 98919845A EP 0980257 A1 EP0980257 A1 EP 0980257A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vlp
- antigen
- vlps
- virus
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des préparations adjuvantes qui contiennent des particules de type viral (VLP) incapables de se répliquer. On peut dériver les VLP à partir d'un virus quelconque parmi plusieurs virus; elles peuvent servir à renforcer la réaction immunologique à un antigène choisi, l'antigène étant différent des particules.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4526297P | 1997-05-01 | 1997-05-01 | |
US45262P | 1997-05-01 | ||
PCT/US1998/008146 WO1998050071A1 (fr) | 1997-05-01 | 1998-04-22 | Utilisation de particules de type viral en tant qu'adjuvants |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0980257A1 true EP0980257A1 (fr) | 2000-02-23 |
Family
ID=21936887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98919845A Withdrawn EP0980257A1 (fr) | 1997-05-01 | 1998-04-22 | Utilisation de particules de type viral en tant qu'adjuvants |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0980257A1 (fr) |
JP (1) | JP2002508748A (fr) |
AU (1) | AU750702B2 (fr) |
CA (1) | CA2288129A1 (fr) |
WO (1) | WO1998050071A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1031346E (pt) * | 1999-01-27 | 2002-09-30 | Idea Ag | Vacinacao nao invasiva atraves da pele |
PT1221968E (pt) | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
US7094882B2 (en) | 2000-04-21 | 2006-08-22 | Yeda Research And Development Co. Ltd. | Growth factor which acts through erb b-4 rtk |
US20030099668A1 (en) * | 2001-09-14 | 2003-05-29 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
NZ537002A (en) * | 2002-06-20 | 2006-06-30 | Cytos Biotechnology Ag | VLPs bound to immunostimulatory substances for use as adjuvants mixed with an antigen for enhancing immune response |
DK1523329T3 (da) * | 2002-07-05 | 2013-10-14 | Folia Biotech Inc | Viruspartikeladjuvant |
US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
AU2003279770A1 (en) | 2002-10-01 | 2004-04-23 | Novartis Vaccines And Diagnostics, Inc. | Anti-cancer and anti-infectious disease compositions and methods for using same |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CN100560719C (zh) | 2003-03-26 | 2009-11-18 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
JP4855250B2 (ja) | 2004-03-31 | 2012-01-18 | ジェノミディア株式会社 | 抗腫瘍作用を有する組成物 |
EP1773403B1 (fr) | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Adjuvants à base d'alphavirus |
WO2006063974A2 (fr) * | 2004-12-13 | 2006-06-22 | Cytos Biotechnology Ag | Jeux ordonnes d'antigenes il-15 et leurs utilisations |
ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
AT502275B8 (de) * | 2005-08-08 | 2007-08-15 | Greenhills Biotechnology Res D | Immunantwort-induzierende zusammensetzungen |
AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
EP1797895A1 (fr) | 2005-12-16 | 2007-06-20 | Pevion Biotech Ltd. | Un système adjuvant comportant des virosomes et liposomes |
CN101466720B (zh) | 2006-06-12 | 2013-01-02 | 赛托斯生物技术公司 | 向rna噬菌体的病毒样颗粒内包装寡核苷酸的方法 |
DK2066354T3 (da) | 2006-09-29 | 2013-05-27 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formuleringer |
CA2669485C (fr) * | 2006-11-15 | 2017-01-03 | Folia Biotech Inc. | Vaccins contre la grippe a base du virus de la mosaique du papayer |
EP2078086A4 (fr) * | 2006-11-15 | 2010-06-30 | Folia Biotech Inc | Systèmes d'antigène conjugué par affinité immunogène fondés sur le virus de la mosaïque de la papaye et utilisation de ceux-ci |
US8586728B2 (en) | 2006-12-12 | 2013-11-19 | Cytos Biotechnology Ag | Oligonucleotides containing high concentrations of guanine monomers |
MX2009007942A (es) * | 2007-01-26 | 2010-06-01 | Folia Biotech Inc | Vacunas basadas en virus del mosaico de la papaya contra salmonella typhi y otros patogenos enterobacterianos. |
WO2008109686A2 (fr) * | 2007-03-05 | 2008-09-12 | Neurok Pharma Llc | Particules recombinantes de type du virus de l'hépatite c non infectieuses et leurs applications pharmaceutiques |
CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
EP2244695A1 (fr) | 2007-12-07 | 2010-11-03 | Novartis AG | Compositions utilisées pour induire des réponses immunitaires |
EP2241626B1 (fr) * | 2008-01-09 | 2016-01-06 | Konkuk University Industrial Cooperation Corp | Vaccins à base de baculovirus |
GB2459436A (en) * | 2008-04-08 | 2009-10-28 | Henderson Morley Plc | Vaccine adjuvant |
KR101507822B1 (ko) | 2008-06-04 | 2015-04-24 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법 |
AU2009279456B2 (en) * | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
WO2010059689A2 (fr) * | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Vlp rsv f et procédés de fabrication et d'utilisation de celui-ci |
EP2447277A1 (fr) | 2010-10-28 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Compositions de vaccin basées sur des immunogènes gp41 modifiés |
DK3299030T3 (da) | 2011-07-11 | 2022-09-05 | Takeda Vaccines Inc | Parenterale norovirus-vaccineformuleringer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
CA1319101C (fr) * | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Proteine de capside nucleique de rotavirus avec ou sans peptides liants comme porteurs de macromolecules immunologiques |
PT100090A (pt) * | 1991-02-04 | 1993-07-30 | Univ Saskatchewan | Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6 |
ATE182791T1 (de) * | 1991-05-08 | 1999-08-15 | Schweiz Serum & Impfinst | Wiederhergestellte influenza-virosomen mit immunostimulierenden und immunoverstärkenden eigenschaften und diese enthaltende impfstoffe |
JP3828570B2 (ja) * | 1991-07-19 | 2006-10-04 | ザ・ユニバーシティ・オブ・クイーンズランド | パピローマウイルスワクチン |
EP0642355B1 (fr) * | 1992-05-23 | 1998-07-15 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccins combines contenant des antigenes de surface du virus de l'hepatite b et d'autres antigenes |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
-
1998
- 1998-04-22 WO PCT/US1998/008146 patent/WO1998050071A1/fr not_active Application Discontinuation
- 1998-04-22 AU AU72545/98A patent/AU750702B2/en not_active Ceased
- 1998-04-22 CA CA002288129A patent/CA2288129A1/fr not_active Abandoned
- 1998-04-22 EP EP98919845A patent/EP0980257A1/fr not_active Withdrawn
- 1998-04-22 JP JP54812898A patent/JP2002508748A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9850071A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU7254598A (en) | 1998-11-27 |
WO1998050071A1 (fr) | 1998-11-12 |
AU750702B2 (en) | 2002-07-25 |
CA2288129A1 (fr) | 1998-11-12 |
JP2002508748A (ja) | 2002-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU750702B2 (en) | Use of virus-like particles as adjuvants | |
EP1221968B1 (fr) | Procede d'obtention de reponses immunes cellulaires de proteines | |
Ellis | New technologies for making vaccines | |
AU741902B2 (en) | Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants | |
US7371391B2 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
AU2007252296A1 (en) | Immunogenic compositions | |
Donaldson et al. | Virus-like particles, a versatile subunit vaccine platform | |
CA2349505A1 (fr) | Produits de recombinaison d'acide nucleique pour immunisation genetique | |
US20020039584A1 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
Tagliamonte et al. | Virus-like particles | |
CA2295740A1 (fr) | Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn | |
US7182947B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
NZ501308A (en) | Use of virus-like particles as adjuvants for increasing immune response | |
Lomada et al. | A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens | |
AU766005B2 (en) | Minimal promoters and uses thereof | |
Fields et al. | What biotechnology has to offer vaccine development | |
US6881723B1 (en) | Nucleic acid constructs | |
Zuckerman | Prospects for vaccines against HIV. | |
AU771286B2 (en) | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants | |
Rappuoli | Current developments in new vaccines for adolescents | |
EP1486215A2 (fr) | Mutants détoxifies de toxines bactériennes ribolysant l'ADP utilisés comme adjuvants parentéraux | |
Zuckerman | Bioengineering of hepatitis B vaccines | |
et Vaccins | lmmunogenic forms of inactivated cytokines; used with recombinant HIB virus-1 env peptide and genuine-depleted virus in vaccine against AIDS | |
T-Lymphocyte | Hepatitis B Surface Antigen Vector Delivers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030910 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20031030 |